ArticleFrontiers in immunology2026
Favorable safety and immunogenicity of a combined quadrivalent influenza and recombinant SARS-CoV-2 vaccine in Sprague-Dawley rats for both primary and booster immunization.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The concurrent circulation of influenza viruses and SARS‑CoV‑2 continues to strain global public health systems. Vaccination remains the cornerstone of defense, and combined vaccines offer a strategic advantage by simplifying logistics, reducing costs, and improving coverage. Methods: In this set of studies, we evaluated the safety and immunogenicity of a novel combined quadrivalent influenza and recombinant COVID‑19 vaccine (developed by Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.), known as the Flu‑CoV2 vaccine, in Sprague‑Dawley rats. Three independent studies were conducted in accordance with ICH S6(R1) guidelines for Preclinical Safety Evaluation of Biotechnology‑Derived Pharmaceuticals: primary immunization (Study 1) and booster immunization following a prior history of either influenza (Study 2) or COVID‑19 (Study 3) vaccination. Immunogenicity was determined by immunoglobulin G (IgG) antibody enzyme‑linked immunosorbent assay, plaque reduction neutralization tests for SARS‑CoV‑2, and hemagglutination inhibition assays for influenza viruses. Results: No severe, life‑threatening, or fatal adverse reactions occurred during any of the studies. Transient injection‑site nodules in adjuvanted groups resolved completely, and all transient post‑vaccination shifts in hematologic and biochemical parameters normalized by the end of the recovery period. As a primary regimen, the Flu‑CoV2 vaccine effectively induced strong IgG and neutralizing antibody responses against both influenza and SARS‑CoV‑2. Administered as a booster, it markedly augmented specific antibody levels in pre‑immune models, demonstrating its potential to broadly enhance recall immune responses. Conclusions: These preclinical data demonstrate a favorable safety profile and potent immunogenicity, supporting the further development of the Flu‑CoV2 vaccine as a promising tool to address the dual threat of influenza and COVID‑19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.